Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Researchers track Long-Term safety of experimental eye cancer treatment

NCT ID NCT07338968

Knowledge-focused Sponsor: Aura Biosciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 20, 2026 · Updated 2 times

Summary

This study is a long-term follow-up for 100 people who completed a previous trial of bel-sar, an experimental treatment for early choroidal melanoma (a type of eye cancer). Participants will not receive any new treatment but will be monitored for about 5 more years to check for side effects and see how they are doing. The goal is to gather safety data over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Aug 2033

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Subjects who have received bel-sar or sham treatment in the Aura-sponsored clinical trial AU-011-301. NCT NCT06007690

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have received bel-sar or sham treatment in the Aura-sponsored clinical trial AU-011-301. * Be willing and able to consent to the AU-011-403 study. Exclusion Criteria: * None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Choroidal melanoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

malignant choroid melanoma Uveal Melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Choroidal melanoma Indeterminate lesions

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Austin Retina Associates Ophthalmology/Retina

    Austin, Texas, 78705, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • Retina Associates of Utah

    Salt Lake City, Utah, 84107, United States

  • Retina Center of Texas

    Southlake, Texas, 76092, United States

  • Retina Consultants of Carolina

    Greenville, South Carolina, 29605, United States

  • Retina Consultants of Oklahoma

    Oklahoma City, Oklahoma, 73112, United States

  • Retinal Consultants Medical Group, Inc.

    Sacramento, California, 95825, United States

  • Tennessee Retina, PC

    Nashville, Tennessee, 37421, United States

  • University of Wisconsin Madison

    Madison, Wisconsin, 53705, United States

  • W.K. Kellogg Eye Center - University of Michigan

    Ann Arbor, Michigan, 48105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.